Happening Now

The Technology Behind Bone Marrow Cellular Processing: The PXP® System

Cell therapies involve the transfer of live cells into a patient to help treat, prevent or potentially cure diseases. One category of cell therapy focuses specifically on the use of stem cells, or cells within the body that have the potential to replace those that are lost through injury or disease. Their versatility and ability … Continued

Breaking Down ThermoGenesis’ Recent Patent for Its Breakthrough Serological Test Reader Technology

ThermoGenesis recently announced that the United States Patent and Trademark Office (USPTO) has accepted a patent application for the company’s new breakthrough lateral flow immunoassay test reader technology.   What is an Antibody Lateral Flow Immunoassay Test? An antibody lateral flow immunoassay (LFIA) test is a simple diagnostic device used to confirm the presence or … Continued

ThermoGenesis Distributes FDA Emergency Use Authorized COVID-19 Antibody Test Kit. What Does it Mean?

ThermoGenesis recently announced it has entered into a supply agreement with Biohit Healthcare to distribute its COVID-19 Antibody Test Kit. This agreement is significant because  Biohit Healthcare has already received Emergency Use Authorization from the U.S. Food and Drug Administration.   What is Emergency Use Authorization? The U.S. Food and Drug Administration (FDA) plays an … Continued

The Technology Behind Cord Blood Processing: AXP® II System

Cells are the basic building blocks of all biological life. Within these cells are small sections of proteins in DNA that possess all our genetic information, called genes. According to The Human Genome Project, it’s estimated that humans have between 20,000 and 25,000 genes. These genes all carry vital instructions for making proteins, which in … Continued

Convalescent Plasma Therapy for Coronavirus Patients

As scientists around the world work tirelessly to design new medicines for COVID-19, doctors have turned to convalescent plasma therapy to see if it could be a viable treatment option for coronavirus. While conservative measurements place the widespread availability of a coronavirus vaccine around somewhere in early 2021, convalescent plasma may potentially serve as a … Continued

How COVID-19 Testing Works

COVID-19 tests have proven to be crucial in measuring the spread of the novel coronavirus (SARS-CoV-2) and helping us better understand how to navigate the current global pandemic. Testing has received a large amount of media attention in recent months, but the information has not always been clear.  The most frequent misconception is that there … Continued

Coronavirus Myths – Fact vs. Fiction

Since the Coronavirus pandemic began, we’ve been bombarded with endless and often competing information. In the ensuing months, the internet, and social media in particular, has been a place where many have gotten their news. Some of that information has been useful, while some of it has just been conspiracy theories and outright false claims. … Continued

Driving CAR-T Manufacture Optimization through Technology Innovation

Cell & Gene Therapy Insights Latest advances in CAR-T cell manufacture & clinical developments PHILIP H COELHO, Founder and Chief Technology Officer (CTO) of ThermoGenesis Corp., the device Division of Cesca Therapeutics (is an engineer/inventor, educated at the University of California, Davis, where he specialized in thermodynamics and machine design. He has been awarded more … Continued

Cut Price Kymriah? ThermoGenesis Thinks So with Automated CAR-T Technology

How CAR-T Automation is Primed to Change the Industry In August​, Novartis made history when its product Kymriah (tisagenlecleucel) became the first chimeric antigen receptor (CAR) T-cell therapy to win US approval. The product is made by collecting a patient’s cells through apheresis at a specialised clinic before shipping them to a manufacturing site where … Continued

With New Patent, Cesca Eyes Faster, Less Costly CAR-T Cell Production

Chimeric antigen receptor T-cell receptor (CAR-T) and CAR-modified natural killer (CAR-NK) therapeutics can be produced faster and at less cost, Cesca Therapeutics says, through the cellular processing technology covered by a recently awarded patent. Cesca said Friday, July 28, 2017 that U.S. Patent No. 9,695,394, titled “Cell Separation Devices, Systems, and Methods,” has been awarded … Continued

How may we help?